{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:55Z","timestamp":1707525655483},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.7759\/cureus.51434","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T10:44:42Z","timestamp":1704105882000},"source":"Crossref","is-referenced-by-count":0,"title":["Underprescription of Fibrate Among Patients With Diabetic Retinopathy in Perak, Malaysia"],"prefix":"10.7759","author":[{"given":"Jazlan","family":"Jamaluddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Azzahi","family":"Mohamed Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"National Health and Morbidity Survey 2015 (NHMS 2015). Vol. II: Non-Communicable Diseases, Risk Factors & Other Health Problems","author":"Institute for Public Health","year":"2015","unstructured":"Institute for Public Health. National Health and Morbidity Survey 2015 (NHMS 2015). Vol. II: Non-Communicable Diseases, Risk Factors & Other Health Problems. Ministry of Health Malaysia, Kuala Lumpur, Malaysia; 2015."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021, 9:e144-60. 10.1016\/S2214-109X(20)30489-7","journal-title":"Lancet Glob Health"},{"key":"ref3","unstructured":"Ministry of Health Malaysia. National Diabetes Registry Report 2020. (2020). https.\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/Rujukan\/NCD\/Diabetes\/National_Diabetes_Registry_Report_2020.pdf."},{"key":"ref4","unstructured":"National Eye Database. The 11th Report of the National Eye Database 2017. (2017). https.\/\/www.acrm.org.my\/ned\/NEDreport\/NED_report_2017.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.9734\/BJMMR\/2014\/7893","article-title":"Current clinical status and vascular complications among patients with type 2 diabetes mellitus at tertiary hospitals in Malaysia","volume":"4","author":"Tan MC","year":"2014","unstructured":"Tan MC, Ng OC, Wong TW, Hejar AR, Joseph A. Current clinical status and vascular complications among patients with type 2 diabetes mellitus at tertiary hospitals in Malaysia. JAMMR. 2014, 4:2896-909. 10.9734\/BJMMR\/2014\/7893","journal-title":"JAMMR"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdm.2010.08.001","article-title":"Current clinical status and complications among type 2 diabetic patients in Universiti Sains Malaysia Hospital","volume":"2","author":"Abougalambou SSI","year":"2010","unstructured":"Abougalambou SSI, Mohamed M, Sulaiman SAS, Abougalambou AS, Hassali MA. Current clinical status and complications among type 2 diabetic patients in Universiti Sains Malaysia Hospital. Int J Diabetes Mellit. 2010, 2:184-8. 10.1016\/j.ijdm.2010.08.001","journal-title":"Int J Diabetes Mellit"},{"key":"ref7","article-title":"Prevention of Blindness from Diabetes Mellitus: Report of a WHO Consultation in Geneva, Switzerland, 9-11 November 2005","author":"World Health Organization","year":"2005","unstructured":"World Health Organization. Prevention of Blindness from Diabetes Mellitus: Report of a WHO Consultation in Geneva, Switzerland, 9-11 November 2005. World Health Organization, Geneva, Switzerland; 2005."},{"key":"ref8","article-title":"Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus (6th Edition)","author":"Ministry of Health Malaysia","year":"2021","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus (6th Edition). Malaysian Health Technology Assessment Section (MaHTAS), Putrajaya, Malaysia; 2021."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2018.02.18","article-title":"Effects of lipid-lowering agents on diabetic retinopathy: a meta-analysis and systematic review","volume":"11","author":"Shi R","year":"2018","unstructured":"Shi R, Zhao L, Wang F, et al.. Effects of lipid-lowering agents on diabetic retinopathy: a meta-analysis and systematic review. Int J Ophthalmol. 2018, 11:287-95. 10.18240\/ijo.2018.02.18","journal-title":"Int J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.12.16","article-title":"Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice","volume":"15","author":"Ngah NF","year":"2022","unstructured":"Ngah NF, Muhamad NA, Abdul Aziz RA, et al.. Fenofibrate for the prevention of progression of non-proliferative diabetic retinopathy: review, consensus recommendations and guidance for clinical practice. Int J Ophthalmol. 2022, 15:2001-8. 10.18240\/ijo.2022.12.16","journal-title":"Int J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech A","year":"2007","unstructured":"Keech A, Mitchell P, Summanen P, et al.. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007, 370:1687-97. 10.1016\/S0140-6736(07)61607-9","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew EY","year":"2010","unstructured":"Chew EY, Ambrosius WT, Davis MD, et al.. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010, 363:233-44. 10.1056\/NEJMoa1001288","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1439","article-title":"Effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials","volume":"45","author":"Preiss D","year":"2022","unstructured":"Preiss D, Spata E, Holman RR, Coleman RL, Lovato L, Ginsberg HN, Armitage J. Effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials. Diabetes Care. 2022, 45:e1-2. 10.2337\/dc21-1439","journal-title":"Diabetes Care"},{"key":"ref14","article-title":"Diabetic Retinopathy Guidelines","author":"The Royal College of Ophthalmologists","year":"2012","unstructured":"The Royal College of Ophthalmologists. Diabetic Retinopathy Guidelines. The Royal College of Ophthalmologists, London, UK; 2012."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes--2013","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013, 36:S11-66. 10.2337\/dc13-S011","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2014079","article-title":"Ministry of Health clinical practice guidelines: diabetes mellitus","volume":"55","author":"Goh SY","year":"2014","unstructured":"Goh SY, Ang SB, Bee YM, et al.. Ministry of Health clinical practice guidelines: diabetes mellitus. Singapore Med J. 2014, 55:334-47. 10.11622\/smedj.2014079","journal-title":"Singapore Med J"},{"key":"ref17","unstructured":"Clinical Practice Guidelines. Screening of diabetic retinopathy. (2011). https.\/\/www.moh.gov.my\/moh\/attachments\/6601.pdf."},{"key":"ref18","article-title":"Clinical Practice Guidelines: Management of Dyslipidaemia 2023. 6th Edition","author":"Ministry of Health Malaysia","year":"2023","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines: Management of Dyslipidaemia 2023. 6th Edition. National Heart Association of Malaysia, Kuala Lumpur, Malaysia; 2023."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0633","article-title":"Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy","volume":"140","author":"Meer E","year":"2022","unstructured":"Meer E, Bavinger JC, Yu Y, VanderBeek BL. Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2022, 140:529-32. 10.1001\/jamaophthalmol.2022.0633","journal-title":"JAMA Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013318.pub2","article-title":"Fenofibrate for diabetic retinopathy","volume":"6","author":"Kataoka SY","year":"2023","unstructured":"Kataoka SY, Lois N, Kawano S, Kataoka Y, Inoue K, Watanabe N. Fenofibrate for diabetic retinopathy. Cochrane Database Syst Rev. 2023, 6:CD013318. 10.1002\/14651858.CD013318.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-019-0488-9","article-title":"Statins and\/or fibrates for diabetic retinopathy: a systematic review and meta-analysis","volume":"11","author":"Mozetic V","year":"2019","unstructured":"Mozetic V, Pacheco RL, Latorraca CO, Riera R. Statins and\/or fibrates for diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019, 11:92. 10.1186\/s13098-019-0488-9","journal-title":"Diabetol Metab Syndr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2020.11.19","article-title":"Descriptive assessment on diabetic retinopathy screening in an awareness programme in Malaysia","volume":"13","author":"Ngah NF","year":"2020","unstructured":"Ngah NF, Muhamad NA, Asnir ZZ, et al.. Descriptive assessment on diabetic retinopathy screening in an awareness programme in Malaysia. Int J Ophthalmol. 2020, 13:1808-13. 10.18240\/ijo.2020.11.19","journal-title":"Int J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56080385","article-title":"Association of fenofibrate and diabetic retinopathy in type 2 diabetic patients: a population-based retrospective cohort study in Taiwan","volume":"56","author":"Lin YC","year":"2020","unstructured":"Lin YC, Chen YC, Horng JT, Chen JM. Association of fenofibrate and diabetic retinopathy in type 2 diabetic patients: a population-based retrospective cohort study in Taiwan. Medicina (Kaunas). 2020, 56:385. 10.3390\/medicina56080385","journal-title":"Medicina (Kaunas)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0024","article-title":"Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study","volume":"39","author":"The ACCORDION Eye Study Group","year":"2016","unstructured":"The ACCORDION Eye Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care. 2016, 39:1089-100. 10.2337\/dc16-0024","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.353","article-title":"Use of fibrates in the United States and Canada","volume":"305","author":"Jackevicius CA","year":"2011","unstructured":"Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA. 2011, 305:1217-24. 10.1001\/jama.2011.353","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v28i6.15","article-title":"Factors influencing prescribing decisions of physicians: a review","volume":"28","author":"Davari M","year":"2018","unstructured":"Davari M, Khorasani E, Tigabu BM. Factors influencing prescribing decisions of physicians: a review. Ethiop J Health Sci. 2018, 28:795-804. 10.4314\/ejhs.v28i6.15","journal-title":"Ethiop J Health Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2098","article-title":"Determinants of adherence to diabetes medications: findings from a large pharmacy claims database","volume":"38","author":"Kirkman MS","year":"2015","unstructured":"Kirkman MS, Rowan-Martin MT, Levin R, Fonseca VA, Schmittdiel JA, Herman WH, Aubert RE. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015, 38:604-9. 10.2337\/dc14-2098","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111270","article-title":"The effect of cost on adherence to prescription medications in Canada","volume":"184","author":"Law MR","year":"2012","unstructured":"Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG. The effect of cost on adherence to prescription medications in Canada. CMAJ. 2012, 184:297-302. 10.1503\/cmaj.111270","journal-title":"CMAJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.663","article-title":"Cost-effectiveness of combined treatment of metformin and fenofibrate on retinopathy progression","volume":"16","author":"Hren R","year":"2013","unstructured":"Hren R, Cerovic R. Cost-effectiveness of combined treatment of metformin and fenofibrate on retinopathy progression. Value Health. 2013, 16:A438. 10.1016\/j.jval.2013.08.663","journal-title":"Value Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.1221","article-title":"Follow-up status in adult type 2 diabetes mellitus: experience from a large Malaysian cohorts. [PREPRINT]","author":"Chew BH","year":"2013","unstructured":"Chew BH, Ismail M, Shariff-Ghazali S, et al.. Follow-up status in adult type 2 diabetes mellitus: experience from a large Malaysian cohorts. [PREPRINT]. Diabetes Technol Ther. 2013, 10.1089\/dia.2012.1221","journal-title":"Diabetes Technol Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.51866\/oa1171","article-title":"A clinical audit of the diagnosis and management of chronic kidney disease in a primary care clinic","volume":"16","author":"Jamaluddin J","year":"2021","unstructured":"Jamaluddin J, Mohamed Yassin MS, Jamil SN, Mohamed Kamel MA, Yusof MY. A clinical audit of the diagnosis and management of chronic kidney disease in a primary care clinic. Malays Fam Physician. 2021, 16:68-76. 10.51866\/oa1171","journal-title":"Malays Fam Physician"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1S050","article-title":"Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults","volume":"47","author":"Lo-Ciganic WH","year":"2013","unstructured":"Lo-Ciganic WH, Boudreau RM, Gray SL, et al.. Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother. 2013, 47:984-92. 10.1345\/aph.1S050","journal-title":"Ann Pharmacother"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14998","article-title":"Frequency and predictors of inappropriate medication dosages for cardiovascular disease prevention in chronic kidney disease patients: a retrospective cross-sectional study in a Malaysian primary care clinic","volume":"9","author":"Jamaluddin J","year":"2023","unstructured":"Jamaluddin J, Mohamed-Yassin MS, Jamil SN, Mohamed Kamel MA, Yusof MY. Frequency and predictors of inappropriate medication dosages for cardiovascular disease prevention in chronic kidney disease patients: a retrospective cross-sectional study in a Malaysian primary care clinic. Heliyon. 2023, 9:e14998. 10.1016\/j.heliyon.2023.e14998","journal-title":"Heliyon"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/197770-underprescription-of-fibrate-among-patients-with-diabetic-retinopathy-in-perak-malaysia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:27Z","timestamp":1707509547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/197770-underprescription-of-fibrate-among-patients-with-diabetic-retinopathy-in-perak-malaysia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.51434","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}